The first FDA-approved anti-VEGF for diabetic retinopathy (DR) with or without DME 1

DR Progression | Efficacy | Safety | Patient Cases


Significant regression in diabetic retinopathy

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with diabetic retinopathy, and for treatment of patients with diabetic macular edema (DME).

RISE & RIDE: Patients With DME

Protocol S: Patients With or Without DME


CI, confidence interval; VA, visual acuity; VEGF, vascular endothelial growth factor. 

DR Progression | Efficacy | Safety | Patient Cases

Resources for your patients.
LUCENTIS Co-pay Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.